Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza challenge study of modRNA and saRNA vaccines in healthy adults
ISRCTN13789612Phase 2Completed
- Sponsor
- hVIVO
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of influenza modRNA vaccine, influenza saRNA vaccine and quadrivalent influenza vaccine in influenza (5 arms), sponsored by hVIVO. Primary endpoints: Area under the viral load-time curve by qRT-PCR, Peak viral load by qRT-PCR and 2 more. Started Dec 2022; status: completed.
02
Drugs
influenza modRNA vaccineinfluenza saRNA vaccinequadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on ISRCTN13789612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13789612.